BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Rethinking Combination Cancer Therapy with Experiments\, Computati
 on\, and Clinical Data
DTSTART:20190313T141500
DTEND:20190313T151500
DTSTAMP:20260511T094907Z
UID:041d42937d24df7f924105b715470318e2c2f77579d31f46994d069b
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr. Adam C. Palmer\, Harvard University\, Boston\, MA (USA)\nB
 IOENGINEERING SEMINAR\n\nAbstract:\nDeveloping optimal drug combinations i
 s one of the central challenges of cancer treatment research: drug combina
 tions are used to treat most types of cancer\, and are almost exclusively 
 responsible for cures of advanced cancers. However\, historically successf
 ul combination therapies were developed empirically\, and the mechanistic 
 basis for their efficacy has been largely speculative. I will present stud
 ies of clinically successful combination therapies that identify the contr
 ol of between-tumor and within-tumor heterogeneity by independently active
  drugs as critical contributors to the efficacy of drug combinations in hu
 man patients. Mathematical descriptions of heterogeneity in cellular or pa
 tient populations\, and experimental measurements of how drug combinations
  address heterogeneity\, lead to accurate predictions of clinical trial re
 sults across many types of cancer and types of therapies\, including curat
 ive chemotherapy regimens and recent immunotherapies. These results have b
 road significance for the treatment of cancers\, for the interpretation of
  clinical trials\, and point to new opportunities to use combination thera
 pies with greater precision.\n\nBio:\nAdam Palmer is  a postdoctoral fell
 ow with Peter K. Sorger at Harvard Medical School's Laboratory of Systems 
 Pharmacology and Department of Systems Biology. He applies experiments and
  computation to understand and to develop combination cancer therapies\, w
 ith particular focus on the origins and therapeutic consequences of cell-t
 o-cell and patient-to-patient heterogeneity in cancers.\nHe completed his 
 Ph.D in Systems Biology at Harvard University with Roy Kishony\, researc
 hing the relationships between mechanisms of drug action and the evolution
  of drug resistance. He got his  B.Sc (Honours) at The University of Adel
 aide\, Australia\, where he completed majors in Biochemistry\, Chemistry\,
  and Physics\, and researched gene regulation by protein traffic on DNA.\n
 \nZoom link for attending remotely: https://epfl.zoom.us/j/229779872
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR